The conference day includes executive panels outlining capital market dynamics, big pharma market appetite, clinical, regulatory and commercialisation drivers, finance raising & partnerships and emerging healthcare models.
There are also 4x intimate and practical workshops on clinical development, regulatory approval, licensing strategies and market access and reimbursement.
Registration and Breakfast
Keynote Presentation: Capital Markets Outlook
Marshall Smith, Head of Global Healthcare, Goldman Sachs
Pharma Panel: Strategic Shifts in Addressing Pipeline Drift; Pharma M&A and Partnering in 2020
Not withstanding the legacy factors continuing to influence strong deal flow, how is Pharma responding to the emerging encroachment of tech giants into their territories? Does this present co-operation opportunities or unwelcome competition and how will this impact external M&A, partnering and consolidation strategies?
Moderator: Senior Executive, Goldman Sachs TBC
Jay Stamatis, Vice President, Head of Business Development and Acquisitions, Abbvie
Veronique Riethuisen, SVP, Global Head of Business Development & Alliance Management, Ipsen
Philippe Lopes-Fernandes, SVP, Global Head of BD & Alliance Management, Merck Serono
Beyhan Zaim, SVP, Commercial Business Development, Novo Nordisk
Nigel Sheail, Global Head of Mergers & Acquisitions and Business Development & Licensing, Novartis
Corporate Investor Panel: Nothing Ventured, Nothing Gained; Backing Bigger Rounds and Making Bigger Bets
With the size of the average investment rounds getting bigger across the entire venture industry how are CVCs aligning with this trend? What can we expect to see from CVCs in terms of leading investment rounds and how is the macro environment affecting the approaches CVCs are taking. Plus, executives share some insights into their current investment preferences.
Peter Dudek, Partner, MRL Ventures Fund
Priyanka Rohatgi, Managing Director, Head, Ipsen Ventures
Michal Silverberg, Managing Director, Novartis Venture Fund
Adam Houghton, Vice President and Head, AbbVie Ventures
Executive Panel: Raising the Bar; Making the ‘Series’ A Grade
In an industry becoming increasingly defined by weighty Series A’s, executives who have been instrumental in achieving strategically significant early-stage venture raises share their success stories and war stories in equal measure. Plus, share what we can expect to see from their companies as they continue to deploy their capital.
David De Graaf, CEO, Comet Therapeutics
Alexandra Gluckmann, CEO, Cedilla Therapeutics
Michael Pavia, CEO, Tuned Therapeutics
Andrew ElBardissi, Principal, Deerfield Management
Executive Panel: Leveraging Strategic Partnerships to Accelerate the progress of your molecule(s)
Executives who have taken their company through key clinical milestones debate the key challenge and success factors in finding the right partners, patient recruitment and risk management approaches to take their assets cost-effectively and punctually through clinical trials.
Moderator: Kenneth Barr, SVP, Head of Discovery Services, Syngene
Additional panelists details to follow shortly
Executive Panel: De-Risking the Regulatory Approval Path - How to Optimize Your Investment Dollars
The path to global product approval is notorious for hurdles from every angle; from technical/scientific risk to regulatory and market access risk. The hurdles are even more evident when there is limited or no precedent for the indication being sought that could impact time, cost and approvability. Executives explore the best ways to minimize these risks and probe cases that address these issues during development, sharing de-risking strategies for keep innovative programs on track.
Moderator: Laurie Smaldone Alsup, MD, CSO, NDA Group
Ed Kaye, CEO, Stoke Therapeutics
Ailis Tweed-Kent, CEO, Cocoon Biotech
John Glasspool, CEO, Anthos Therapeutics
Christine Swenson, Head, Regulatory Affairs, Moderna Therapeutics
Keynote Chat: The Rationale of AI in Healthcare? It’s Human Nature
Ted Tanner Jr., CTO and Chief Architect, Watson Health, IBM
Jay Sales, Director, Advanced Technology, VSP Global
Executive Panel: Commercialization; the Alternative to the Traditional Exit Strategy
The importance of a robust development and commercialization strategy has never been more evident. With decades of experience between them, executives discuss the considerations needed as your drug progresses through the developmental phases towards the market and share their advice on how to minimize the risk that your company’s therapy will end up a commercial failure.
Moderator: Senior executive from IQVIA
Additional panelists details to follow shortly
Executive Panel: Movers, Shakers and Therapeutic Deal Makers
With lofty biotech valuations and rising competition in key therapeutic fields, executives who have positioned their companies as attractive for deal making opportunities share their experiences, KSFs and fundamentals when engaging big pharm. Plus executives share what we can expect to see from their respective companies in the year ahead.
Rogerio Vivaldi, CEO, Sigilon Therapeutics
Deanna Petersen, CBO, AvroBio
Kelly Gold, Vice President, Corporate Development, CAMP4 Therapeutics
Nouhad Husseini, Vice President, Head of Business Development, Regeneron Pharmaceuticals
Constantine Chinoporos, CBO, Boston Pharmaceuticals
Closing Panel: Knocking on the Door; the Booming Direct-to-Consumer (D2C) Healthcare Model
With tech players increasingly encroaching in healthcare, forcing companies — as well as startups — to think of different ways to reach patients, and investors wagering that consumers will be increasingly willing to shop for healthcare the same way they buy more traditional products online, what can we expect from the D2C model?
Joel Wishkovsky, CEO, Simple Health
Melissa Fensterstock, Co-Founder and CEO, Lansdowne Labs
Carolyn Witte, Co-Founder and CEO, Tia
Nicole Kholodnov, VP of Clinical Operations, Parsley Health
Networking Drinks & Close of Conference